Skip to main content

Advertisement

Log in

Serum levels of bcl-2 in patients with colorectal cancer

  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Background

Many recent studies focus on the immunohistochemical evaluation of Bcl-2 expression, and its prognostic significance in colorectal cancer (CRC). Our aim was to investigate the presence of bcl-2 protein in the serum and to examine the association between its levels, stage and tumour load, in patients with CRC.

Methods

A commercially available ELISA was used for the estimation of bcl-2 levels, in 94 patients with different stages of CRC. Forty-eight healthy blood donors served as controls. Concentrations ranging 2SD above and below the controls median were accepted as “normal”.

Results

bcl-2 was detected in the serum of patients with CRC. A significantly higher proportion of patients with non-metastatic disease (61%), had high serum bcl-2 values, compared to patients with metastatic disease (28%, p<0.0001).

Conclusions

Serum bcl-2 in patients with CRC may reflect the degree of Bcl-2 expression in cancer tissue. Serum bcl-2 is easily determinable, and could be useful as a prognostic marker in CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K. Giannoulis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giannoulis, K., Fountzilas, G., Angouridakis, N. et al. Serum levels of bcl-2 in patients with colorectal cancer. Tech Coloproctol 8 (Suppl 1), s56–s58 (2004). https://doi.org/10.1007/s10151-004-0112-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-004-0112-2

Key words

Navigation